Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Pharmacokinetics of KBP-5074 in Patients With Moderate-to-Severe Chronic Kidney Disease and Uncontrolled Hypertension

X
Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Pharmacokinetics of KBP-5074 in Patients With Moderate-to-Severe Chronic Kidney Disease and Uncontrolled Hypertension

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ocedurenone (Primary)
  • Indications Renal hypertension
  • Focus Therapeutic Use
  • Acronyms BLOCKCKD
  • Sponsors KBP Biosciences
  • Most Recent Events

    • 20 Jul 2023 Results of subgroup Analysis of the BLOCK-CKD Study assessing efficacy and safety of Ocedurenone published in the American Journal of Hypertension
    • 07 Nov 2022 Results of subgroup analysis evaluating Effect of Ocedurenone in Patients With Uncontrolled Hypertension and Stage 3b/4 Chronic Kidney Disease , presented at the American Heart Association Scientific Sessions 2022.
    • 30 Aug 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top